Indication from Summary of Product Characteristics
PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
References:1. Mosele F,
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386.
2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
3. Chalhoub C,Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150.
4. Piqray® (alpelisib) EU Summary of Product Characteristics. Novartis; May 2021.
5. André F,Ciruelos E,Rubovszky G,et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.
This is an international site for PIQRAY® (alpelisib) and is intended for healthcare professionals outside the US.
The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local Novartis representative for local prescribing information via
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)
US HCPs & Other Country-Specific Websites
Below is a list of the countries that host a PIQRAY website based on local label and in a local language. They are intended for healthcare professionals (HCPs) only. If you are an HCP from one of the countries listed below, click on your country's link to be redirected to your country's PIQRAY website.